Pidnarulex (CX-5461)
Solid Tumors with HRD
Key Facts
About Senhwa Biosciences
Senhwa Biosciences is a clinical-stage oncology company developing innovative small molecule inhibitors of the DNA Damage Response (DDR), with its lead asset, silmitasertib (CX-4945), targeting Casein Kinase 2 (CK2). The company has advanced multiple programs into mid-stage clinical trials, exploring both monotherapy and combination strategies in cholangiocarcinoma, medulloblastoma, and COVID-19. Its strategy is to exploit tumor-specific genetic vulnerabilities to achieve synthetic lethality and enhance the efficacy of existing cancer therapies, positioning itself in the high-growth targeted oncology and DDR inhibitor space.
View full company profile